{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=47", "query": { "condition": "Diagnosis of Melanoma", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 1873, "total_pages": 188, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T10:59:46.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01721746", "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "BMS-936558", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 405, "start_date": "2012-12-21", "completion_date": "2020-12-29", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 32, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francciso", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721746" }, { "nct_id": "NCT01519427", "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "selumetinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-01", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-06-18", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New Brunswick, New Jersey • Nashville, Tennessee + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519427" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT01449279", "title": "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-10", "completion_date": "2016-12-01", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449279" }, { "nct_id": "NCT00003597", "title": "Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant human thrombopoietin", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "1998-11", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 23, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003597" }, { "nct_id": "NCT00412828", "title": "A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Stage III or Stage IV Melanoma" ], "interventions": [ { "name": "CR011-vcMMAE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CuraGen Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2006-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 4, "location_summary": "Santa Monica, California • New Haven, Connecticut • New York, New York + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412828" }, { "nct_id": "NCT00333502", "title": "Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2006-05", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • Farmington, New Mexico", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Farmington", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333502" }, { "nct_id": "NCT01191775", "title": "A Study of PNT2258 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Lymphoma", "Prostate Cancer", "Melanoma" ], "interventions": [ { "name": "PNT2258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2010-08", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191775" }, { "nct_id": "NCT00585000", "title": "A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "CP-675,206", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2007-12", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585000" }, { "nct_id": "NCT05075993", "title": "Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Esophageal", "Gastric Cancer", "Metastatic Head and Neck Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic HPV Related Solid Tumors", "Metastatic Ovarian Carcinoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "LVGN3616 + LVGN6051 + Nab-Paclitaxel", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 352, "start_date": "2021-11-12", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-05T10:59:46.495Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05075993" } ] }